Develop STAT3 Disorder Treatment
Budget: ₹750 – ₹1,250 INR
I need expert help to push forward a viable treatment—or ideally a cure—for a rare STAT3-related genetic disorder that affects immune regulation. I do not yet have a defined therapeutic avenue or existing datasets, so your first task will be to analyse the current scientific landscape and propose the most promising strategy, whether that turns out to be gene therapy, small-molecule drug design, antisense oligos, or another innovative approach.
What I expect from you:
• A concise scientific brief summarising the disease mechanism, available targets, and recent peer-reviewed findings.
• A step-by-step development plan covering in-silico work, in-vitro validation, and in-vivo or ex-vivo models, with go/no-go decision points.
• Clear resource requirements and realistic timelines through IND-enabling studies.
• Regulatory considerations for FDA/EMA orphan-drug or rare-disease pathways.
If you already have experience bringing orphan-disease therapies from concept to clinic, please highlight specific examples and any publications or patents. A background in molecular biology, immunology, or pharmacology—along with familiarity with CRISPR, viral vectors, or structure-based drug design—will be invaluable.
I am ready to move quickly once a rigorous, evidence-backed plan is in front of me.
What I expect from you:
• A concise scientific brief summarising the disease mechanism, available targets, and recent peer-reviewed findings.
• A step-by-step development plan covering in-silico work, in-vitro validation, and in-vivo or ex-vivo models, with go/no-go decision points.
• Clear resource requirements and realistic timelines through IND-enabling studies.
• Regulatory considerations for FDA/EMA orphan-drug or rare-disease pathways.
If you already have experience bringing orphan-disease therapies from concept to clinic, please highlight specific examples and any publications or patents. A background in molecular biology, immunology, or pharmacology—along with familiarity with CRISPR, viral vectors, or structure-based drug design—will be invaluable.
I am ready to move quickly once a rigorous, evidence-backed plan is in front of me.